Introduction: Idiopathic pulmonary fibrosis (IPF) treatment was revolutionized by the advent
of two novel antifibrotics, nintedanib and pirfenidone. However, neither is a panacea and …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive
lung disorder. Previously, it was thought to be a chronic inflammatory disease; however, it is …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a poor prognosis and few
treatment options. However, recent research into this condition has led to considerable …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating, scarring lung disease
with a worse prognosis than some cancers. The incidence of IPF is increasing and while …

ABSTRACT Introduction Idiopathic Pulmonary Fibrosis is a chronic, progressive lung
disease characterized by worsening lung scarring and the radiological/histological pattern of …

Idiopathic pulmonary fibrosis (IPF) is a rare pulmonary disease with a poor prognosis and
severe impact on quality of life. Early diagnosis is still challenging and important delays are …